Liposomal Vitamin D

Liposomal Supplements: What is it and how does it work in the body?

• Lipophilicity is a key property in transport processes, including intestinal absorption, membrane permeability, protein binding, and distribution to different tissues and organs, including the brain. (ScienceDirect)

• Liposomal supplements are about preserving bioavailability. They encapsulate the ingredient in a pocket of fat in a way it survives the digestive tract. Now some supplements benefit from this, some would get wasted. Largely depnding on the solubility of the ingredient. 

• This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations.

• Take for example, Luteolin which has the ability to inhibit the enzyme that allows Fructose into cells. Something as this is significant as it attacks the base processes that quickly lead to insulin resistance and then all of metabolic dysfunction.  This is the first line of defense against metabolic disease and preserving health span.

• However, Luteolin is very water soluble, so most of the research around it is using injection.  However, by using Liposomes it is showing efficacy even as a cancer intervention.  So this is one ingredient that makes an otherwise inert supplement into a potential game changer.

  
  

  A word of caution:

  A lot of liposomal supplements when tested show none of the active ingredients being actually inside the liposomes simply because in order for manufacturers to do it right during the manufacturing process is not easy. However, if it is done correctly, it can truly offer 

  
  

Key Web Sources

•  Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOPNIDDM

  Trail Research Group.

• Yu AQ, Le J, Huang WT, Li B, Liang HX, Wang Q, Liu YT, Young CA, Zhang MY, Qin

  SL. The effects of acarbose on non-diabetic overweight and obese patients: a meta-analysis.

  Adv Ther. 2021;38(2):1275–89. https://doi.org/10.1007/s12325-020-01602-9. Epub 2021

  Jan 9. Erratum in: Adv Ther. 2021 Aug;38(8):4603-4604. PMID: 33421022

• Serrano JS, Jiménez CM, Serrano MI, et al. A possible interaction of potential clinical interest between digoxin and acarbose. Clin Pharmacol Ther. 1996;60:589–92.

• Gerard J, Lefebvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type

  2 diabetics. Eur J Clin Pharmacol. 1984;27:233–6.